Table 1.

Cytotoxicity(IC₅₀, μM) of compounds 1–22 against MDA-MB-435, HepG2 and HT-116 cancer cell lines.

Compounds		IC50 (μM) a
	MDA-MB-435 b	HepG2 b	HCT-116 b
1	3.19 ± 0.92	9.99 ± 0.55	5.69 ± 0.25
2	>50	>50	26.08 ± 1.84
3	3.06 ± 0.13	12.83 ± 0.15	7.55 ± 0.45
4	11.74 ± 1.12	>50	16.57 ± 1.40
5	>50	9.98 ± 1.06	7.54 ± 0.21
6	6.79 ± 1.59	>50	3.29 ± 0.01
7	10.00 ± 1.75	>50	3.14 ± 0.16
8	>50	>50	>50
9	6.31 ± 1.40	10.90 ± 1.40	25.79 ± 0.64
10	1.52 ± 0.72	2.26 ± 0.35	3.42 ± 0.21
11	9.67 ± 1.80	>50	>50
12	5.76 ± 2.75	13.37 ± 2.72	20.70 ± 2.76
13	5.81 ± 2.89	10.09 ± 0.82	9.62 ± 0.20
14	7.25 ± 2.27	11.18 ± 0.94	7.09 ± 0.09
15	7.33 ± 1.20	>50	16.34 ± 0.90
16	7.32 ± 1.04	>50	14.92 ± 1.02
17	>50	11.81 ± 1.45	20.64 ± 1.64
18	1.96 ± 0.58	11.56 ± 1.40	6.49 ± 0.73
19	0.66 ± 0.41	5.04 ± 1.38	2.75 ± 0.23
20	2.06 ± 0.17	>50	2.94 ± 0.10
21	0.62 ± 0.23	1.98 ± 0.34	0.80 ± 0.08
22	0.97 ± 0.24	2.39 ± 0.50	2.69 ± 0.23
Epirubicin c	0.56 ± 0.06	0.96 ± 0.02	0.48 ± 0.03

^a IC₅₀ values are taken as means ± standard deviation from three independent experiments; ^b MDA-MB-435, human breast cancer cell line; HepG2, human liver cancer cell line; HCT-116, human colon cancer cell line; ^c Used as a positive control.